News | May 03, 2024
Bayer secures full ownership in Bayer Zydus Pharma by acquiring remaining 25% stake
The JV successfully leveraged the strengths of both companies to better serve the fast-growing Indian market
The JV successfully leveraged the strengths of both companies to better serve the fast-growing Indian market
Late-breaker Phase 3 STRIDE-10 trial presented as an oral presentation at European Society of Clinical Microbiology and Infectious Diseases
Sales reflect continued strong growth in oncology and vaccines
Open a printable version of this pageEmail the URL of this page to a friend
NULIBRY is a first-in-class synthetic cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A
Commercial terms include research funding and milestones and/or royalty payments to Evotec based on the success of the program
NexGard Spectra is a soft, flavourful monthly chew that kills fleas before they can lay eggs
NM5072 is an anti-Properdin antibody that selectively blocks the alternative pathway while maintaining the integrity of the classical pathway required for fending off infections
SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between Alvotech and Teva
The demand in Africa for COVID-19 vaccines has declined
Subscribe To Our Newsletter & Stay Updated
